Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES.
Adeel Ajwad ButtP YanO S ShaikhA-B Abou-SamraPublished in: Alimentary pharmacology & therapeutics (2017)
HBV-r is relatively uncommon after DAA therapy and not higher than among those treated with a PEG/RBV regimen. The small numbers of persons treated with a DAA regimen who do develop HBV-r have a shortened survival compared to those without HBV-r.